Fecal Calprotectin Test Market

Fecal Calprotectin Test Market (Patient Type: Adult and Pediatric; Assay Type: ELISA [Enzyme Linked Immunosorbent Assay], Enzyme Fluoroimmunoassay, and Quantitative Immune-chromatography) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Fecal Calprotectin Test Market Outlook 2031

  • The global industry was valued at US$ 126.9 Mn in 2022
  • It is projected to advance at a CAGR of 10.7% from 2023 to 2031 to reach more than US$ 355.8 Mn by the end of 2031

Analysts’ Viewpoint

The global fecal calprotectin test market is expected to witness significant growth in the next few years due to rise in prevalence of inflammatory bowel disease (IBD) and gastrointestinal disorders. Fecal calprotectin test is most commonly used in adult patients due to high incidence rate of inflammatory bowel disease (IBD) and colorectal cancer among these patients. Increase in awareness among patients and healthcare professionals about the benefits of early diagnosis and treatment is expected to drive global fecal calprotectin test market growth.

Development of more accurate and low cost fecal calprotectin tests offers lucrative opportunities to market players. Companies are focusing on developing cost-efficient and more precise tests in order to increase market share and revenue. However, high cost of tests and lack of reimbursement policies in some regions are likely to hamper market growth.

Fecal Calprotectin Test Market

Global Fecal Calprotectin Test Market Introduction

The stool calprotectin test is a diagnostic tool used to measure the level of calprotectin in the stool. Calprotectin is a protein released by white blood cells in the intestines during inflammation, making it a useful marker for various gastrointestinal disorders, particularly inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis.

The stool calprotectin test is non-invasive and provides valuable information to healthcare professionals in assessing the severity of intestinal inflammation, monitoring disease activity, and determining treatment strategies. It is often used in combination with other clinical evaluations and imaging techniques to aid in the diagnosis and management of gastrointestinal conditions.

The two types of fecal calprotectin test available in the market are quantitative and qualitative. The quantitative test measures the exact amount of calprotectin in the stool, while the qualitative test provides a positive or negative result based on a predetermined threshold.

The quantitative test is more accurate and provides a more precise measurement of calprotectin levels, but it is also more expensive. The qualitative test is less expensive and provides a quick and easy result, but it is less accurate and may lead to false positives or false negatives.

Fecal calprotectin normal range is 10 to 50 or 60 μg/mg. The treatment for high calprotectin levels includes anti-inflammatory medicine, which helps to reduce inflammation in diseases such as IBD, colorectal cancer, and others.

Rise in Prevalence of IBD Drives Global Fecal Calprotectin Test Market

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that includes Crohn's disease and ulcerative colitis. Prevalence of IBD is increasing globally, particularly in developed countries.

According to the Centers for Disease Control and Prevention (CDC), around 3 million adults in the U.S. have been diagnosed with IBD. In Europe, the prevalence of IBD is estimated to be 0.3% to 0.5% of the total population.

Several factors contribute to the increasing prevalence of IBD, including:

  • Environmental Factors: Changes in diet, exposure to pollutants, and hygiene practices have been linked to the development of IBD. For instance, a Western-style diet that is high in fat and low in fiber has been associated with increased risk of developing IBD.
  • Genetic Factors: Genetic factors are believed to play a role in the development of IBD. Studies have shown that people with a family history of IBD are at increased risk of developing the condition.
  • Age: IBD can occur at any age, but it is most commonly diagnosed in people between the ages of 15 and 35
  • Geographic Location: Prevalence of IBD varies by geographic location, with higher rates observed in developed countries
  • Smoking: Smoking has been identified as a risk factor for Crohn's disease, but it appears to have a protective effect against ulcerative colitis

Rise in prevalence of IBD is driving demand for accurate and reliable diagnostic tools such as fecal calprotectin testing. Early detection and treatment of IBD can help improve patient outcomes and reduce the risk of complications. Hence, demand for non-invasive diagnostic tests such as fecal calprotectin testing is high.

Non-invasive Procedure Fueling Demand for Fecal Calprotectin Testing

Non-invasiveness of fecal calprotectin testing is a major driver of the global fecal calprotectin test market. Fecal calprotectin testing is a non-invasive diagnostic tool used to evaluate gastrointestinal inflammation and is increasingly being used in the diagnosis and management of inflammatory bowel disease (IBD) and other gastrointestinal disorders.

Unlike other diagnostic tests, such as colonoscopy or biopsy, fecal calprotectin testing does not require insertion of any devices or instruments into the body. Instead, patients provide a stool sample, which is analyzed in a laboratory to measure the level of calprotectin in the stool. This non-invasive nature of fecal calprotectin testing can be particularly appealing to patients who could be hesitant to undergo more invasive diagnostic procedures.

Non-invasiveness of fecal calprotectin testing also makes it a convenient diagnostic tool for healthcare providers. Fecal calprotectin testing can be performed quickly and easily in a clinical setting, and the results are typically available within a few days. This convenience and ease of use could help to encourage more widespread adoption of fecal calprotectin testing, which is likely to drive the fecal calprotectin test market size.

Increase in Demand for Fecal Calprotectin Testing among Adults

In terms of patient type, the adults segment is anticipated to account for the largest global fecal calprotectin test market share during the forecast period. This can be ascribed to increase in demand for fecal calprotectin testing among adult patients. According to the National Health Service, people of any age can get IBD, but it is usually diagnosed in patients aged between 15 and 40.

Increase in number of adults suffering from gastrointestinal disorders is likely to drive the segment during the forecast period. According to a survey conducted by the Sahlgrenska Academy at the University of Gothenburg in 2020, nearly 40% of adults were suffering from a functional gastrointestinal disorder.

Functional gastrointestinal disorders represent a series of chronic disorders in the gastrointestinal tract that often include severe symptoms, including heartburn, acid reflux, and dyspepsia in the upper gastrointestinal tract and chronic constipation, abdominal distention or bloating, and irritable bowel syndrome in the lower gastrointestinal tract.

High Accuracy and Lost Cost Fueling Demand for ELISA Test

Based on assay type, the enzyme linked immunosorbent assay (ELISA) segment dominated the global fecal calprotectin test market in 2022. The ELISA test for fecal calprotectin is highly accurate and can detect levels as low as 15-20 μg/g of stool. It is a non-invasive diagnostic tool that is less costly and less time-consuming than more invasive diagnostic procedures such as endoscopy or colonoscopy.

The ELISA test for fecal calprotectin is particularly useful for the diagnosis and monitoring of inflammatory bowel disease (IBD) and can also be used to distinguish between IBD and non-IBD conditions with similar symptoms, such as irritable bowel syndrome (IBS).

Increase in Number of Patients Suffering from IBD

In terms of indication, the inflammatory bowel disease segment accounted for leading share of the global market in 2022. Fecal calprotectin test is major inflammatory bowel disease test used for diseases diagnosis.

Fecal calprotectin test is primarily used in the diagnosis and monitoring of inflammatory bowel disease (IBD), which typically affects adults. IBD, including Crohn's disease and ulcerative colitis, is a chronic condition that causes inflammation in the gut, leading to symptoms such as abdominal pain, diarrhea, and rectal bleeding. Fecal calprotectin test is also referred as GI inflammation test.

Fecal calprotectin test helps to distinguish between IBD and IBS. Increase in number of patients suffering from inflammatory bowel disease is likely to drive the segment. According to the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), there are 10 million people globally living with IBD. However, the number could be higher, if the same prevalence of 1% or more that is true in the U.K. and the U.S. applies to most other western countries.

Availability of Advanced Infrastructure and Professionals Bolstering Hospitals Segment

Based on end-user, the hospitals segment dominated the global fecal calprotectin test market in 2022. Hospitals are one of the primary end-users of fecal calprotectin tests, which are used for the diagnosis and monitoring of patients with inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis.

Presence of large, specialized hospitals equipped with advanced health care infrastructure and specialist professionals for consulting boosts patient preference for hospitals. Availability of a wide range of services in hospital settings is likely to propel the segment during the forecast period.

Regional Outlook of Global Fecal Calprotectin Test Market

Europe is a major market for fecal calprotectin tests. This can be ascribed to high prevalence of IBDs, such as Crohn's and ulcerative colitis; availability of advanced healthcare infrastructure & facilities; and presence of several key market players.

Germany dominated the market in Europe in 2022 owing to factors such as large number of IBD patients, high adoption of new technologically advanced products, significant health care expenditure, early availability of advanced technologies, and increase in research activities across the country.

Asia Pacific is anticipated to be the fastest growing region for fecal calprotectin test during the forecast period. The market in the region is anticipated to expand at a high CAGR from 2022 to 2031 due to large patient base in countries such as India and China and rise in awareness about IBD and colorectal cancer.

Analysis of Key Players

The global fecal calprotectin test market is fragmented, with the presence of large number of leading players. Manufactures in calprotectin test are investing significantly in research & development, primarily to develop innovative fecal calprotectin test. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the key players in the market.

Abbexa, ALPCO, Alpha Laboratories, Biomerica, BÜHLMANN Laboratories AG, DRG INSTRUMENTS GMBH, EagleBio, Epitope Diagnostics, Inc., OPERON, S.A., R-Biopharm AG, Svar Life Science, Thermo Fisher Scientific, Inc., Werfen, SENTINEL CH. SpA, Diazyme Laboratories, Inc., and DiAgam are the key players operating in the global market.

Key Developments Global Fecal Calprotectin Test Market

  • In September 2022, Epitope Diagnostics developed a Stool Sample Quantitative Collection and Extraction Device (sQED, US Patent pending). This sQED allows for the easy and accurate collection and extraction of stool specimens without the need for the traditional weighing process. This device also standardizes the collection process, and the extracted sample can be directly used in an automated immunoassay system.
  • In June 2022, R-Biopharm AG, an international leader in biotechnology, announced the acquisition of AusDiagnostics. With the addition of Australia-based expert and producer of molecular biology multiplex diagnostics, extraction reagents, and laboratory automation equipment, R-Biopharm plans to expand its product line.

The fecal calprotectin test industry research report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Fecal Calprotectin Test Market Snapshot

Attribute Detail

Size Value in 2022

US$ 126.9 Mn

Forecast (Value) in 2031

More than US$ 355.8 Mn

Growth Rate (CAGR)

10.7%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Mn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Patient Type
    • Adult
    • Pediatric
  • Assay Type
    • ELISA (Enzyme linked Immunosorbent Assay)
    • Enzyme Fluoroimmunoassay
    • Quantitative Immune-chromatography
  • Indication
    • Inflammatory Bowel Disease
    • Colorectal Cancer
    • Celiac Disease
  • End-user
    • Hospitals
    • Diagnostic Laboratories
    • Academic & Research Institutes

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Abbexa
  • ALPCO
  • Alpha Laboratories
  • Biomerica
  • BÜHLMANN Laboratories AG
  • DRG Instruments GmbH
  • EagleBio
  • Epitope Diagnostics, Inc.
  • OPERON, S.A.
  • R-Biopharm AG
  • Svar Life Science
  • Thermo Fisher Scientific Inc.
  • Werfen
  • SENTINEL CH. SpA
  • Diazyme Laboratories, Inc.
  • DiAgam

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global fecal calprotectin test market in 2022?

The global industry was valued at US$ 126.9 Mn in 2022

How big will the fecal calprotectin test business be in 2031?

It is projected to reach more than US$ 355.8 Mn by 2031

How will the fecal calprotectin test industry grow during the forecast period?

The industry is anticipated to expand at a CAGR of 10.7% from 2023 to 2031

Which factors are driving demand for fecal calprotectin tests?

Rise in prevalence of inflammatory bowel disease (IBD) and non-invasive nature of fecal calprotectin testing are driving the market

Which region will account for major market share of the fecal calprotectin test during the forecast period?

Europe is projected to account for major market share during the forecast period

Who are the prominent fecal calprotectin test players?

Abbexa, ALPCO, Alpha Laboratories, Biomerica, BÜHLMANN Laboratories AG, DRG Instruments GmbH, EagleBio, Epitope Diagnostics, Inc., OPERON, S.A., R-Biopharm AG, Svar Life Science, Thermo Fisher Scientific, Inc., Werfen, SENTINEL CH. SpA, Diazyme Laboratories Inc., and DiAgam are the prominent players in the market

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Fecal Calprotectin Test Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Patient Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Fecal Calprotectin Test Market Analysis and Forecast, 2017-2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Technological Advancement

        5.2. Diseases Epidemiology

        5.3. Regulatory Scenario

        5.4. Pricing Analysis

        5.5. COVID-19 Impact Analysis

    6. Global Fecal Calprotectin Test Market Analysis and Forecast, by Patient Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Patient Type, 2017-2031

            6.3.1. Adult

            6.3.2. Pediatric

        6.4. Market Attractiveness Analysis, by Patient Type

    7. Global Fecal Calprotectin Test Market Analysis and Forecast, by Assay Type

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Assay Type, 2017-2031

            7.3.1. ELISA (Enzyme linked Immunosorbent Assay)

            7.3.2. Enzyme Fluoroimmunoassay

            7.3.3. Quantitative Immune-chromatography

        7.4. Market Attractiveness Analysis, by Assay Type

    8. Global Fecal Calprotectin Test Market Analysis and Forecast, by Indication

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Indication, 2017-2031

            8.3.1. Inflammatory Bowel Disease

            8.3.2. Colorectal Cancer

            8.3.3. Celiac Disease

        8.4. Market Attractiveness Analysis, by Indication

    9. Global Fecal Calprotectin Test Market Analysis and Forecast, by End-user

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by End-user, 2017-2031

            9.3.1. Hospitals

            9.3.2. Diagnostic Laboratories

            9.3.3. Academic & Research Institutes

        9.4. Market Attractiveness Analysis, by End-user

    10. Global Fecal Calprotectin Test Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, by Region

    11. North America Fecal Calprotectin Test Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Patient Type, 2017-2031

            11.2.1. Adult

            11.2.2. Pediatric

        11.3. Market Value Forecast, by Assay Type, 2017-2031

            11.3.1. ELISA (Enzyme linked Immunosorbent Assay)

            11.3.2. Enzyme Fluoroimmunoassay

            11.3.3. Quantitative Immune-chromatography

        11.4. Market Value Forecast, by Indication, 2017-2031

            11.4.1. Inflammatory Bowel Disease

            11.4.2. Colorectal Cancer

            11.4.3. Celiac Disease

        11.5. Market Value Forecast, by End-user, 2017-2031

            11.5.1. Hospitals

            11.5.2. Diagnostic Laboratories

            11.5.3. Academic & Research Institutes

        11.6. Market Value Forecast, by Country, 2017-2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Patient Type

            11.7.2. By Assay Type

            11.7.3. By Indication

            11.7.4. By End-user

            11.7.5. By Country

    12. Europe Fecal Calprotectin Test Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Patient Type, 2017-2031

            12.2.1. Adult

            12.2.2. Pediatric

        12.3. Market Value Forecast, by Assay Type, 2017-2031

            12.3.1. ELISA (Enzyme linked Immunosorbent Assay)

            12.3.2. Enzyme Fluoroimmunoassay

            12.3.3. Quantitative Immune-chromatography

        12.4. Market Value Forecast, by Indication, 2017-2031

            12.4.1. Inflammatory Bowel Disease

            12.4.2. Colorectal Cancer

            12.4.3. Celiac Disease

        12.5. Market Value Forecast, by End-user, 2017-2031

            12.5.1. Hospitals

            12.5.2. Diagnostic Laboratories

            12.5.3. Academic & Research Institutes

        12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Italy

            12.6.5. Spain

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Patient Type

            12.7.2. By Assay Type

            12.7.3. By Indication

            12.7.4. By End-user

            12.7.5. By Country/Sub-region

    13. Asia Pacific Fecal Calprotectin Test Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Patient Type, 2017-2031

            13.2.1. Adult

            13.2.2. Pediatric

        13.3. Market Value Forecast, by Assay Type, 2017-2031

            13.3.1. ELISA (Enzyme linked Immunosorbent Assay)

            13.3.2. Enzyme Fluoroimmunoassay

            13.3.3. Quantitative Immune-chromatography

        13.4. Market Value Forecast, by Indication, 2017-2031

            13.4.1. Inflammatory Bowel Disease

            13.4.2. Colorectal Cancer

            13.4.3. Celiac Disease

        13.5. Market Value Forecast, by End-user, 2017-2031

            13.5.1. Hospitals

            13.5.2. Diagnostic Laboratories

            13.5.3. Academic & Research Institutes

        13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Patient Type

            13.7.2. By Assay Type

            13.7.3. By Indication

            13.7.4. By End-user

            13.7.5. By Country/Sub-region

    14. Latin America Fecal Calprotectin Test Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Patient Type, 2017-2031

            14.2.1. Adult

            14.2.2. Pediatric

        14.3. Market Value Forecast, by Assay Type, 2017-2031

            14.3.1. ELISA (Enzyme linked Immunosorbent Assay)

            14.3.2. Enzyme Fluoroimmunoassay

            14.3.3. Quantitative Immune-chromatography

        14.4. Market Value Forecast, by Indication, 2017-2031

            14.4.1. Inflammatory Bowel Disease

            14.4.2. Colorectal Cancer

            14.4.3. Celiac Disease

        14.5. Market Value Forecast, by End-user, 2017-2031

            14.5.1. Hospitals

            14.5.2. Diagnostic Laboratories

            14.5.3. Academic & Research Institutes

        14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Patient Type

            14.7.2. By Assay Type

            14.7.3. By Indication

            14.7.4. By End-user

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Fecal Calprotectin Test Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Patient Type, 2017-2031

            15.2.1. Adult

            15.2.2. Pediatric

        15.3. Market Value Forecast, by Assay Type, 2017-2031

            15.3.1. ELISA (Enzyme linked Immunosorbent Assay)

            15.3.2. Enzyme Fluoroimmunoassay

            15.3.3. Quantitative Immune-chromatography

        15.4. Market Value Forecast, by Indication, 2017-2031

            15.4.1. Inflammatory Bowel Disease

            15.4.2. Colorectal Cancer

            15.4.3. Celiac Disease

        15.5. Market Value Forecast, by End-user, 2017-2031

            15.5.1. Hospitals

            15.5.2. Diagnostic Laboratories

            15.5.3. Academic & Research Institutes

        15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Patient Type

            15.7.2. By Assay Type

            15.7.3. By Indication

            15.7.4. By End-user

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competitive Matrix (by tier and size of companies)

        16.2. Market Share Analysis, by Company (2022)

        16.3. Company Profiles

            16.3.1. Abbexa

                16.3.1.1. Company Overview

                16.3.1.2. Drug Class Portfolio

                16.3.1.3. SWOT Analysis

                16.3.1.4. Financial Overview

                16.3.1.5. Strategic Overview

            16.3.2. ALPCO

                16.3.2.1. Company Overview

                16.3.2.2. Drug Class Portfolio

                16.3.2.3. SWOT Analysis

                16.3.2.4. Financial Overview

                16.3.2.5. Strategic Overview

            16.3.3. Alpha Laboratories

                16.3.3.1. Company Overview

                16.3.3.2. Drug Class Portfolio

                16.3.3.3. SWOT Analysis

                16.3.3.4. Financial Overview

                16.3.3.5. Strategic Overview

            16.3.4. Biomerica

                16.3.4.1. Company Overview

                16.3.4.2. Drug Class Portfolio

                16.3.4.3. SWOT Analysis

                16.3.4.4. Financial Overview

                16.3.4.5. Strategic Overview

            16.3.5. BÜHLMANN Laboratories AG

                16.3.5.1. Company Overview

                16.3.5.2. Drug Class Portfolio

                16.3.5.3. SWOT Analysis

                16.3.5.4. Financial Overview

                16.3.5.5. Strategic Overview

            16.3.6. DRG Instruments GmbH

                16.3.6.1. Company Overview

                16.3.6.2. Drug Class Portfolio

                16.3.6.3. SWOT Analysis

                16.3.6.4. Financial Overview

                16.3.6.5. Strategic Overview

            16.3.7. EagleBio

                16.3.7.1. Company Overview

                16.3.7.2. Drug Class Portfolio

                16.3.7.3. SWOT Analysis

                16.3.7.4. Financial Overview

                16.3.7.5. Strategic Overview

            16.3.8. Epitope Diagnostics, Inc.

                16.3.8.1. Company Overview

                16.3.8.2. Drug Class Portfolio

                16.3.8.3. SWOT Analysis

                16.3.8.4. Financial Overview

                16.3.8.5. Strategic Overview

            16.3.9. OPERON, S.A.

                16.3.9.1. Company Overview

                16.3.9.2. Drug Class Portfolio

                16.3.9.3. SWOT Analysis

                16.3.9.4. Financial Overview

                16.3.9.5. Strategic Overview

            16.3.10. R-Biopharm AG

                16.3.10.1. Company Overview

                16.3.10.2. Drug Class Portfolio

                16.3.10.3. SWOT Analysis

                16.3.10.4. Financial Overview

                16.3.10.5. Strategic Overview

            16.3.11. Svar Life Science

                16.3.11.1. Company Overview

                16.3.11.2. Drug Class Portfolio

                16.3.11.3. SWOT Analysis

                16.3.11.4. Financial Overview

                16.3.11.5. Strategic Overview

            16.3.12. Thermo Fisher Scientific, Inc.

                16.3.12.1. Company Overview

                16.3.12.2. Drug Class Portfolio

                16.3.12.3. SWOT Analysis

                16.3.12.4. Financial Overview

                16.3.12.5. Strategic Overview

            16.3.13. Werfen

                16.3.13.1. Company Overview

                16.3.13.2. Drug Class Portfolio

                16.3.13.3. SWOT Analysis

                16.3.13.4. Financial Overview

                16.3.13.5. Strategic Overview

            16.3.14. SENTINEL CH. SpA

                16.3.14.1. Company Overview

                16.3.14.2. Drug Class Portfolio

                16.3.14.3. SWOT Analysis

                16.3.14.4. Financial Overview

                16.3.14.5. Strategic Overview

            16.3.15. Diazyme Laboratories, Inc.

                16.3.15.1. Company Overview

                16.3.15.2. Drug Class Portfolio

                16.3.15.3. SWOT Analysis

                16.3.15.4. Financial Overview

                16.3.15.5. Strategic Overview

            16.3.16. DiAgam

                16.3.16.1. Company Overview

                16.3.16.2. Drug Class Portfolio

                16.3.16.3. SWOT Analysis

                16.3.16.4. Financial Overview

                16.3.16.5. Strategic Overview

    List of Tables

    Table 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031

    Table 02: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

    Table 03: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 04: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 05: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 06: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 07: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031

    Table 08: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

    Table 09: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 10: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 11: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 12: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031

    Table 13: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

    Table 14: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 15: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 16: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 17: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031

    Table 18: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

    Table 19: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 20: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 21: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031

    Table 23: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

    Table 24: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 25: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 26: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 27: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Product Type, 2017-2031

    Table 28: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

    Table 29: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 30: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    List of Figures

    Figure 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031

    Figure 02: Global Fecal Calprotectin Test Market Value Share, by Patient Type, 2022

    Figure 03: Global Fecal Calprotectin Test Market Value Share, by Assay Type, 2022

    Figure 04: Global Fecal Calprotectin Test Market Value Share, by Indication, 2022

    Figure 05: Global Fecal Calprotectin Test Market Value Share, by End-user, 2022

    Figure 06: Global Fecal Calprotectin Test Market Value Share, by Region, 2022

    Figure 07: Global Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031

    Figure 08: Global Fecal Calprotectin Test Market (US$ Mn), by Adult, 2017-2031

    Figure 09 Global Fecal Calprotectin Test Market (US$ Mn), by Pediatric, 2017-2031

    Figure 10: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031

    Figure 11: Global Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031

    Figure 12: Global Fecal Calprotectin Test Market (US$ Mn), by ELISA (Enzyme linked Immunosorbent Assay), 2017-2031

    Figure 13 Global Fecal Calprotectin Test Market (US$ Mn), by Enzyme Fluoroimmunoassay, 2017-2031

    Figure 14: Global Fecal Calprotectin Test Market (US$ Mn), by Quantitative Immune-chromatography, 2017-2031

    Figure 15: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031

    Figure 16: Global Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 17: Global Fecal Calprotectin Test Market (US$ Mn), by Inflammatory Bowel Disease, 2017-2031

    Figure 18: Global Fecal Calprotectin Test Market (US$ Mn), by Colorectal Cancer, 2017-2031

    Figure 19: Global Fecal Calprotectin Test Market (US$ Mn), by Celiac Disease, 2017-2031

    Figure 20: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 21: Global Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 22: Global Fecal Calprotectin Test Market (US$ Mn), by Hospitals, 2017-2031

    Figure 23: Global Fecal Calprotectin Test Market (US$ Mn), by Diagnostic Laboratories, 2017-2031

    Figure 24: Global Fecal Calprotectin Test Market (US$ Mn), by Academic & Research Institutes, 2017-2031

    Figure 25: Global Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 26: Global Fecal Calprotectin Test Market Value Share Analysis, by Region, 2022 and 2031

    Figure 27: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Region, 2023-2031

    Figure 28: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031

    Figure 29: North America Fecal Calprotectin Test Market Value Share Analysis, by Country, 2022 and 2031

    Figure 30: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Country, 2023-2031

    Figure 31: North America Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031

    Figure 32: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031

    Figure 33: North America Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031

    Figure 34: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031

    Figure 35: North America Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 36: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 37: North America Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 38: North America Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 39: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031

    Figure 40: Europe Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 41: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 42: Europe Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031

    Figure 43: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031

    Figure 44: Europe Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031

    Figure 45: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031

    Figure 46: Europe Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 47: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 48: Europe Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 49: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 50: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031

    Figure 51: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 52: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 53: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031

    Figure 54: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031

    Figure 55: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031

    Figure 56: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031

    Figure 57: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 58: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 51: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 60: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 61: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031

    Figure 62: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 63: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 64: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031

    Figure 65: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031

    Figure 66: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031

    Figure 67: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031

    Figure 68: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 69: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 70: Latin America Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 71: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 72: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031

    Figure 73: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 74: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 75: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031

    Figure 76: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031

    Figure 77: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031

    Figure 78: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031

    Figure 79: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 80: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 81: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 82: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 83: Global Fecal Calprotectin Test Market Share, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved